Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.
1. A method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types comprising:
administering to a human in need thereof an immunogenic peptide or protein of at least 10 and up to 88 amino acid residues in length, said peptide or protein having a sequence corresponding to a sequence of corresponding length from the N terminal amino acids 1-88 of a papillomavirus L2 protein,
wherein administration of said immunogenic peptide or protein thereby induces the production of broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types in said human.
2. The method of claim 1 , wherein said peptide or protein has a sequence corresponding to a sequence from the N-terminal amino acids 1-88 of HPV16 L2 protein.
3. The method of claim 1 , wherein said peptide or protein comprises a sequence corresponding to a sequence from the N-terminal amino acids 17-36 of HPV16 L2.
4. The method of claim 1 , wherein said immunogenic peptide or protein is conjugated or fused to an amino acid, protein, or peptide other than a papilloma virus L2 protein or peptide.